China Stock Alerts
Burning Rock Biotech, Ltd.
NASDAQ:
BNR
Headquartered in China and founded in 2014, Burning Rock Biotech, Ltd., whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.
Burning Rock Biotech's business consists of (i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and (ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Ernst & Young LLP
IPO (June 12, 2020)
Cayman Islands
Guangzhou, China
Internal
Analyst Coverage
Latest News
September 1, 2021: Burning Rock Reports Second Quarter 2021 Financial Results | Burning Rock Biotech Limited (brbiotech.com)
May 24, 2021: Burning Rock Reports First Quarter 2021 Financial Results | Burning Rock Biotech Limited (brbiotech.com)
May 13, 2021: Burning Rock to be Added to MSCI China Index | Burning Rock Biotech Limited (brbiotech.com)
April 28, 2021: Burning Rock Schedules First Quarter of 2021 Earnings Release on May 25, 2021 | Burning Rock Biotech Limited (brbiotech.com)
April 13, 2021: Burning Rock’s Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology
March 11, 2021: Burning Rock Biotech Limited American Depositary Shares (BNR) Q4 2020 Earnings Call Transcript
March 10, 2021: Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results
February 8, 2021: Burning Rock Schedules Fourth Quarter of 2020 Earning Release on March 11, 2021